Sandoz has announced the European launch of Afqlir® (aflibercept).
A 2 mg vial kit and pre-filled syringe for intravitreal injection, Afqlir® was approved by the European Commission in November 2024 for the same indications in adult patients as the reference medicine, Eylea® — namely, the treatment of various retinal diseases to prevent disease-related blindness. Studies show that Afqlir® matches the reference medicine in efficacy, safety, and pharmacokinetics. Aflibercept is considered a gold standard for treating various neovascular retinal diseases.
Christophe Delenta, President Europe, Sandoz, said: “Vision loss can devastate lives, affecting not only those living with conditions like nAMD, but also the families and caregivers who support them. At the same time, the high cost of current treatments for neovascular retinal diseases places further strain on healthcare systems. That’s why the launch of Afqlir® is such an important milestone."
Afqlir® was launched in the UK in November 2025, with other major European markets, such as Germany and France, to follow in 2026.
In September 2025, Sandoz also announced that it had reached an agreement with Regeneron Pharmaceuticals, Inc. to resolve all patent disputes between the two companies relating to the FDA-approved aflibercept biosimilar, clearing the path for the launch of Enzeevu™ (aflibercept-abzv) in the US by the end of 2026.
